A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy with Nivolumab in Patients with Advanced Solid Tumors and Hematological Malignancies (NCT04305249)
ERASER
This trial is No longer recruiting
Registration number NCT04305249
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Mark Voskoboynik
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR